miRNA-140-5p: New Avenue for Pulmonary Arterial Hypertension Drug Development?

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank the patients and their families who provides samples to the Sheffield Pulmonary Hypertension Biobank.

Financial & competing interests disclosure

Funding for this research was provided by a Medical Research Council Clinical Research Training Fellowship (AMK Rothman: MR/K002406/1); Medical Research Council Career Development Award (A Lawrie: G0800318); British Heart Foundation Senior Basic Science Fellowship (A Lawrie: FS/13/48/30453) and British Heart Foundation Project Grant (PG/11/11629288). The collection of patient blood samples was coordinated through the Sheffield NIHR Clinical Research Facility. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Funding for this research was provided by a Medical Research Council Clinical Research Training Fellowship (AMK Rothman: MR/K002406/1); Medical Research Council Career Development Award (A Lawrie: G0800318); British Heart Foundation Senior Basic Science Fellowship (A Lawrie: FS/13/48/30453) and British Heart Foundation Project Grant (PG/11/11629288). The collection of patient blood samples was coordinated through the Sheffield NIHR Clinical Research Facility. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.